Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing

(By Sharon Begley for STAT)

When 23andMe received government permission in 2017 to sell health-related genetic testing, it came with several conditions, including that the company tell customers that its brand of testing can miss disease-causing variants. Now, in a study presented on Thursday at the annual meeting of the American Society of Human Genetics, a competitor has analyzed the likelihood of such “false negatives,” concluding that in some ethnic groups the chance that 23andMe’s tests will miss a cancer-causing DNA variant is 100%.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.